ClinicalTrials.gg
CompletedNCT06056557VIRTUEUpdated Sep 2, 2025

Versatility of a Circular Multielectrode Catheter in the Individualized Recognition & Treatment of Atrial Fibrillation and Related Arrhythmias Using Pulsed Field Energy

An interventional study of VARIPULSE™ catheter ablation in Atrial Fibrillation, Paroxysmal or Persistent, Atrial Fibrillation and Flutter and Atrial Flutter Typical, sponsored by Vivek Reddy. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-02.

Sponsored by Vivek Reddy · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Apr 2025, 1 year 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
141
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Atrial Fibrillation by Vivek Reddy — 1 open to participants now, 3 under way, none of them phase 3. Atrial Fibrillation · Vivek Reddy.

Enrollment
5th of 13
141 · median 88
Started
2023
with 1 other
No phase
12 of 14
none open now
Registered
11th of 14
by date

Among the 14 studies in Atrial Fibrillation by Vivek Reddy, this one is the 5th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2023, is one of 12 with no phase, and was the 11th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

1 of the 14 studies in Atrial Fibrillation by Vivek Reddy is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Atrial Fibrillation by Vivek Reddy, or all of them as a file.
02

Study summary

The purpose of this pragmatic study is to evaluate the safety, performance and effectiveness of the VARIPULSE catheter technology used in combination with the TRUPULSE™ Generator, and the compatible EAM system (Carto 3D) to treat patients with atrial fibrillation and related arrhythmias during clinically-indicated ablation procedures.

Read the detailed description

By virtue of its efficiency, safety profile, and potential for improved efficacy in certain patient populations (e.g., thickened atrial tissue of hypertrophic cardiomyopathy (HCM) patients), there is tremendous excitement about the role of pulsed field ablation (PFA) to treat atrial fibrillation and related arrhythmias. However, most PFA clinical trials enroll very selected populations and have highly focused inclusion/exclusion criteria - for example, typically only paroxysmal or persistent atrial fibrillation (AF) patients with upper age criteria are included, other disease states such as HCM are excluded, and typically redo ablation procedures are also excluded. The latter is particularly problematic since redo procedures are quite prevalent in most physicians' clinical practice.

In some sense, the incorporation of these restrictive criteria is not terribly surprising since most of the novel PFA catheters are specifically designed to perform only certain aspects of the AF ablation procedure (e.g., just PVI). That is, when there are more complex substrates (where other types of lesion sets may be needed), it may not be practical to allow a more inclusive criteria for enrollment. Of course, the downside is that the majority of the patients that are eventually treated in clinical practice are not reflected by the enrolled patient population.

The VARIPULSE™ catheter technology is a novel circular catheter with a variable loop design, containing multiple electrodes with individual irrigation pores capable of delivering pulse-field energy.

The Ablation procedure will follow the below sequence:

  • Anatomical and voltage mapping of the left and/or right atrium
  • To perform this mapping, the VARIPULSE bi-directional catheter or a compatible conventional FDA-approved multi-electrode mapping catheter (e.g., Pentaray, Octaray or Optrell) may be used
  • Activation mapping of any-presenting or inducible atrial flutter
  • Pulmonary Vein Isolation (PVI) to be achieved in all patients with atrial fibrillation (if not already achieved).
  • Confirmation of entrance block with adenosine or isoproterenol challenge
  • Additional ablation lesion sets are per the investigator's discretion including:

    • Posterior wall Isolation
    • Regional fractionation clusters
    • Cavo-tricuspid isthmus Line
    • Mitral Isthmus Line
    • Any micro-/macro-reentrant atrial tachycardia's
  • As part of the ablation procedure, any safety assessments that are considered important (e.g., EGD, coronary angiography, etc.) may be performed; these data will also be collected.

This study is a prospective, single-center, non-randomized, interventional clinical study to determine the safety and efficacy in using BWI IRE ablation system in a variety of atrial arrhythmias. Subjects will be followed for 12 months post-procedure.

03

Conditions studied

  • Atrial Fibrillation, Paroxysmal or Persistent
  • Atrial Fibrillation and Flutter
  • Atrial Flutter Typical

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 or older.
  • Diagnosed with atrial fibrillation or atrial atypical atrial flutter (typical flutter may also be ablated provided that the typical flutter occurs in addition to atrial fibrillation or atypical flutter; that is, typical flutter as the sole arrhythmia should not undergo PFA).
  • Previous surgical or catheter ablation for atrial fibrillation is allowed
  • Planned for a catheter ablation procedure
  • Able and willing to provide written consent and comply with all testing and follow-up requirements
  • Have in place or are planned to receive an implantable loop recorder, pacemaker or defibrillator capable of recording atrial rhythm

Exclusion criteria

Exclusion Criteria:

  • Documented "active" left atrial thrombus
  • Conditions that preclude the introduction and manipulation of intracardiac catheters: eg, active intracardiac thrombus, myxoma, tumor, a prohibitive interatrial baffle or patch, etc.)
  • Previous PCI/MI within the past 1 month
  • Active systemic infection or sepsis
  • Uncontrolled heart failure - (NYHA) function class IV.
  • History of blood clotting, bleeding abnormalities or to anticoagulation.
  • Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment.
  • Women who are pregnant, lactating, or who are of childbearing age and plan on becoming pregnant during this trial.
  • or other disease processes likely to limit survival to less than 12 months.
  • Currently enrolled in an study evaluating another device, biologic, or drug, that would interfere with this trial.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
141 participants (actual)

Study arms

  • Experimental
    Interventional

    All patients will receive the intervention. That is, all patients will undergo ablation with the experimental catheter (device).

    Device: VARIPULSE™ catheter ablation

Interventions

  • DeviceVARIPULSE™ catheter ablation

    Subjects will arrive to the electrophysiology laboratory for their ablation procedure and will undergo preparation for the procedure per standard protocol. The purpose of an ablation procedure is to scar or destroy the heart tissue causing the atrial fibrillation. The current FDA approved ablation treatments commonly use freezing, radio frequency, or laser, delivered through a catheter that is threaded through blood vessels to the heart, as the energy source to destroy the abnormal tissue. The BWI IRE VARIPULSE ablation system used in this study uses a type of energy source called pulse field. Pulse field ablation applies ultra-rapid (less than 1 second) electrical fields to the heart muscle to destroy the abnormal tissue. This type of energy is thought to safer and more effective at treating atrial fibrillation. ● For a lesion set that cannot be performed using the VARIPULSE catheter technology, a conventional FDA-approved RF ablation

06

What researchers measure

Primary outcomes

  1. Number of participants with acute procedural success

    Acute procedural success is defined according to the type of arrhythmia, for example: * Entrance block in all targeted PVs for patients treated for atrial fibrillation (Both first and Re-Do) * Termination of atrial flutters for patients presenting in atrial flutter.

    Time frame: up to 12 months post-procedure

Secondary outcomes

  1. Percentage of time spent in atrial flutter/fibrillation/tachycardia

    Percentage of time spent in atrial flutter/fibrillation/tachycardia as noted on CIED interrogation.

    Time frame: up to 12 months post-procedure

  2. Percentage of patients with no evidence of atrial fibrillation/flutter or tachycardia of more than 30 seconds of duration

    The percentage of patients with no evidence of atrial fibrillation/flutter or tachycardia of more than 30 seconds of duration as noted by implantable device after the 3-month blanking period until the end of 12 months of follow-up

    Time frame: after 3-month blanking period until end of 12 months of follow-up

  3. Percentage of patients presenting with persistent atrial fibrillation with no evidence of atrial fibrillation/flutter or tachycardia of more than 30 seconds

    The percentage of patients presenting with persistent atrial fibrillation with no evidence of atrial fibrillation/flutter or tachycardia of more than 30 seconds of duration as noted by implantable device after the 3-month blanking period until the end of 12 months of follow up in patients not taking anti-arrhythmic medications

    Time frame: after 3-month blanking period until end of 12 months of follow-up

  4. Percentage of patients who do not report recurrent of symptomatic arrhythmias

    The percentage of patients who do not report recurrent of symptomatic arrhythmias as noted during telephone or office follow up after the 3-month blanking period until the end of 12 months of follow up

    Time frame: after 3-month blanking period until end of 12 months of follow-up

  5. Percentage of patients taking anti-arrhythmic medications with no evidence of atrial fibrillation/flutter or tachycardia of more than 30 seconds

    The percentage of patients with no evidence of atrial fibrillation/flutter or tachycardia of more than 30 seconds of duration as noted by implantable device after the 3-month blanking period until the end of 12 months of follow up in patients who are taking anti-arrhythmic medications

    Time frame: after 3-month blanking period until end of 12 months of follow-up

  6. Percentage of patients not taking anti-arrhythmic medications with no evidence of atrial fibrillation/flutter or tachycardia of more than 30 seconds of duration

    The percentage of patients with no evidence of atrial fibrillation/flutter or tachycardia of more than 30 seconds of duration as noted by implantable device after the 3-month blanking period until the end of 12 months of follow up in patients who not taking anti-arrhythmic medications

    Time frame: after 3-month blanking period until end of 12 months of follow-up

  7. Durability of lesion sets in any patient that undergoes a second procedure

    Durability of lesion sets in any patient that undergoes a second procedure (Block across attempted lines, absence of electrograms in targeted substrate) as measured with 3-d electroanatomic map to assess bidirectional block across ablation lines.

    Time frame: up to 12 months post-procedure

  8. Number of patient emergency room (ER) visits

    Number of patient emergency room (ER) visits

    Time frame: up to 12 months post-procedure

  9. Number of patient Hospitalizations

    Number of patient Hospitalizations

    Time frame: up to 12 months post-procedure

  10. Number of patients requiring cardioversion

    Measured by the actual occurrence of cardioversion procedures

    Time frame: up to 12 months post-procedure

  11. Number of patients who experience repeat ablation

    Number of patients who experience repeat ablation

    Time frame: up to 12 months post-procedure

07

Study locations

1 site
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
08

References and documents

Individual participant data

Plan to share: No — Data not available/not applicable.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Apr 2025, 18 months.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's 18 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2023
First posted
Sep 28, 2023
StartActual
Sep 28, 2023
Primary completionActual
Apr 18, 2025
CompletionActual
Apr 18, 2025
Last update
Sep 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06056557
Lead sponsor
Vivek Reddy
Responsible party
Vivek Reddy (Professor, Icahn School of Medicine at Mount Sinai) — Sponsor-investigator
First posted
Sep 28, 2023
Start date
Sep 28, 2023
Primary completion
Apr 18, 2025
Completion
Apr 18, 2025
Last update
Sep 2, 2025

Study contacts

Vivek Reddy, MD
principal investigator · Icahn School of Medicine at Mount Sinai

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion